17:10:15 EST Fri 20 Nov 2026
Enter Symbol
or Name
USA
CA



Z:NNVC - NANOVIRICIDES INC - http://www.nanoviricides.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NNVC - Z0.11.03·1.403.01.14-0.03-2.6105.61102421.185  1.19  1.141.93  0.8516:15:00Nov 1715 min RT 2¢

Recent Trades - Last 10 of 242
Time ETExPriceChangeVolume
16:15:00Z1.14-0.031
16:15:00Z1.14-0.031
16:10:04Z1.14-0.031
16:10:04Z1.14-0.031
16:10:04Z1.14-0.031
16:04:04Z1.14-0.031
16:04:03Z1.14-0.031
16:00:12Z1.14-0.031
16:00:12Z1.14-0.031
16:00:12Z1.14-0.031

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-11-17 08:45U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)
2026-11-10 08:45U:NNVCNews ReleaseAn Investigational Drug to Tackle Measles Outbreaks
2026-10-27 09:15U:NNVCNews ReleaseAs Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides
2026-10-20 08:45U:NNVCNews ReleaseNanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
2026-10-13 08:45U:NNVCNews ReleasePhase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
2026-10-06 08:45U:NNVCNews ReleaseNanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
2026-10-05 08:45U:NNVCNews ReleaseNanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
2026-09-29 08:45U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
2026-09-28 08:45U:NNVCNews ReleaseClinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
2026-09-23 08:30U:NNVCNews ReleasePhase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
2026-09-15 09:25U:NNVCNews ReleaseClinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides
2026-09-15 09:00U:NNVCNews ReleaseA $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
2026-09-08 08:30U:NNVCNews ReleaseClinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
2026-08-31 08:30U:NNVCNews ReleaseWhile Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
2026-08-18 08:30U:NNVCNews ReleaseThe Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
2026-08-10 08:30U:NNVCNews ReleaseNanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
2026-07-28 08:30U:NNVCNews ReleaseNanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
2026-07-24 08:00U:NNVCNews ReleaseNanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
2026-07-22 08:30U:NNVCNews ReleaseAs Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
2026-07-13 09:27U:NNVCNews ReleaseAs Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo